Orforglipron vs Survodutide.

Orforglipron (brand: Foundayo, development code LY3502970) is a once-daily, orally administered GLP-1 receptor agonist developed by Eli Lilly. The FDA approved it on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. It is included on this site despite not being a peptide: orforglipron is a small-molecule, non-peptide agonist of the same receptor the injectable GLP-1 peptides target, and it is the closest direct alternative to them, so leaving it out would misrepresent the landscape people are actually choosing between.

Survodutide (BI 456906) is an investigational once-weekly injectable peptide that activates two gut-hormone receptors at once: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is being co-developed by Boehringer Ingelheim and Zealand Pharma as a candidate treatment for obesity and for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). It is not an approved medicine and is available only within regulated clinical trials. The dual-receptor design is intended to combine appetite and blood-sugar effects with an added push on energy expenditure and liver-fat handling.

Orforglipron binds and activates the GLP-1 receptor, the same class B G-protein-coupled receptor engaged by semaglutide, liraglutide and the GLP-1 arm of tirzepatide, producing glucose-dependent insulin secretion, slowed gastric emptying, suppressed glucagon and reduced appetite. The pharmacologically interesting part is how it does this without being a peptide. Work published in Science Translational Medicine (2024, PMID 39693407) characterises the basis for non-peptide agonism at this receptor: the molecule occupies a site that permits receptor activation from a small synthetic scaffold rather than mimicking the native hormone's full peptide sequence. Because it is not a peptide, it is not degraded in the gut the way oral peptide formulations are, which is why it can be taken as a conventional tablet with no food or water timing restrictions, unlike oral semaglutide.

As a GLP-1 receptor agonist, survodutide slows gastric emptying, enhances glucose-dependent insulin secretion, and reduces appetite through central pathways. Its distinguishing feature is simultaneous agonism of the glucagon receptor, which in this metabolic context is thought to raise energy expenditure and promote hepatic fat mobilization. This balanced dual agonism aims to produce greater weight loss and liver benefit than GLP-1 activation alone. The molecule is engineered for a long half-life to permit weekly subcutaneous dosing.

Human evidence is substantial and spans phase 2 through phase 3 in both obesity and type 2 diabetes. A phase 2 trial in adults with obesity (NEJM 2023, PMID 37351564) established dose-dependent weight reduction, and a parallel phase 2 programme in type 2 diabetes reported in The Lancet (2023, PMID 37369232) showed reductions in HbA1c and body weight. Phase 3 results in obesity were published in the New England Journal of Medicine (2025, PMID 40960239), and a separate NEJM report (2025, PMID 40544435) covered early type 2 diabetes. A head-to-head trial against oral semaglutide in adults with type 2 diabetes appeared in The Lancet (2026, PMID 41765029), and a randomized phase 3 maintenance trial was published in Nature Medicine (2026, PMID 42120723). ACHIEVE-5, adding orforglipron to titrated insulin glargine, was reported in JAMA (2026, PMID 42251769). This is a considerably more complete human evidence package than almost anything else discussed in peptide communities, which is the point worth taking from it.

The core efficacy dataset for survodutide comes from a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial published in The Lancet Diabetes & Endocrinology (2024) and sponsored by Boehringer Ingelheim, in which 386 adults with obesity received survodutide (0.6-4.8 mg) or placebo over 46 weeks. Mean body-weight reductions were roughly -6.2%, -12.5%, -13.2% and -14.9% across ascending doses versus -2.8% for placebo under the treatment-policy analysis, with weight loss of nearly 19% among participants who reached and stayed on the highest dose. Weight loss was dose-dependent and had not clearly plateaued by week 46, suggesting further potential with longer treatment. The design limits interpretation: a single dose-finding study, placebo rather than active comparator, a 46 week horizon, and body weight as a surrogate rather than a clinical outcome. Survodutide has also been studied in a Phase 2 MASH trial, where it improved liver histology endpoints relative to placebo, and a later mediation analysis published in Hepatology examined how much of the liver benefit tracked with weight reduction and how much appeared independent of it. Larger Phase 3 obesity and MASH programs are underway to confirm efficacy and long-term safety; results reported so far include a Phase 3 trial of once-weekly survodutide in adults with obesity in the New England Journal of Medicine and the SYNCHRONIZE-MASLD Phase 3 trial in adults with obesity and metabolic dysfunction-associated steatotic liver disease in Nature Medicine. Several gaps remain explicit. There is no dedicated cardiovascular outcome trial result for survodutide, unlike semaglutide, which has published cardiovascular outcome data. There are no head-to-head randomised comparisons against semaglutide or tirzepatide, both of which have completed registrational programs and regulatory approval, so cross-trial percentage comparisons are not reliable. There is no multi-year durability, weight-regain, or paediatric evidence. As an investigational agent, its benefit-risk profile is not yet established.

The adverse-event profile reported across the trials is the familiar GLP-1 class pattern, dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation, generally most pronounced during dose escalation and often diminishing with time. Discontinuation for gastrointestinal reasons occurred in the trials. As an approved product it carries a prescribing label with the full contraindication and warning set for the GLP-1 receptor agonist class, and that label, not this page, is the authoritative safety document. Because it is a prescription medicine, safety monitoring happens through a prescriber rather than self-management, which is a meaningful difference from the research-use-only compounds elsewhere on this site.

In the Phase 2 obesity trial, adverse events were common and predominantly gastrointestinal, including nausea, vomiting and diarrhoea, occurring far more often than with placebo. These effects were most frequent during dose escalation, consistent with the GLP-1 drug class. A slower titration schedule was explored to improve tolerability. Beyond the trial data, the incretin class carries recognised issues that a regulator will expect to see characterised: gallbladder and biliary events, reported cases of pancreatitis, retained gastric contents relevant to sedation and anaesthesia, loss of lean mass alongside fat mass, and rodent thyroid C-cell findings that have shaped labelling for several agents. Glucagon receptor agonism adds its own questions, notably heart rate increases and hepatic parameters, which is why trials of this class typically require scheduled liver chemistry, heart rate and blood pressure monitoring, contraception and pregnancy exclusion, and structured stopping rules for intolerable gastrointestinal effects. Because survodutide is still in trials, rare or long-term risks remain incompletely characterized, and it should only be used under clinical-trial supervision. There is also a supply problem outside that setting: survodutide is not commercially manufactured for patients, so any material offered through grey-market research-chemical channels has no verified identity, potency, purity or sterility, no cold-chain guarantee, and no adverse-event reporting pathway. Contamination and mislabelling in that supply chain are documented concerns for peptides generally, and they compound the fact that the underlying molecule has no established safety profile in unsupervised use.

FDA-approved 1 April 2026 as Foundayo (orforglipron) for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It is a prescription medicine. Approval is indication-specific: an approval for chronic weight management is not a validation of any other use it may be marketed or discussed for. Regulatory status elsewhere in the world varies and should be checked locally.

Survodutide is an investigational drug and has not been approved by the FDA, EMA, or any major regulator for any indication. It carries an FDA Breakthrough Therapy designation for MASH with fibrosis. Any use outside a registered clinical trial is unapproved.